Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Gene analysis and sequencing in treatment of leukemia

Paolo Ghia • 22 Jun 2017
EHA 2017
Leukemia

Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milano, Italy discusses the importance of gene analysis in patients with leukemia. The results form a gene analysis test can determine the optimal therapy for a patient, whether that is treatment with novel inhibitors or immunochemotherapy. It is also crucial to sequence therapies appropriately, as some therapies can become less efficacious in patients, if the patient has had certain prior treatments. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from Paolo Ghia

Fixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLL
1:11
Fixed-duration dose-reduced ibrutinib plus venetoclax: importance of toxicity reduction in CLL
Paolo Ghia • 11 Jun 2026
Is there promise for fixed-duration BTK and BCL2 inhibitor combination therapy in R/R CLL?
0:56
Is there promise for fixed-duration BTK and BCL2 inhibitor combination therapy in R/R CLL?
Paolo Ghia • 11 Jun 2026
Emerging third-generation BTK-targeted therapies for CLL: overcoming BTK resistance
1:22
Emerging third-generation BTK-targeted therapies for CLL: overcoming BTK resistance
Paolo Ghia • 11 Jun 2026
Dose-escalation results from the BELLWAVE-010 study of nemtabrutinib plus venetoclax in R/R CLL
1:29
Dose-escalation results from the BELLWAVE-010 study of nemtabrutinib plus venetoclax in R/R CLL
Paolo Ghia • 11 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals